FDA approves once-daily version of Requip XL

06/16/2008 | Bloomberg

GlaxoSmithKline PLC has received FDA approval to market a new once-daily formulation of Requip XL, a treatment for Parkinson's disease and restless legs syndrome. The new version will "provide smoother blood levels without the peaks and troughs that multiple daily doses typically deliver," a neurology expert said in the company's statement.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL